These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 21856867)

  • 21. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
    Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
    Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
    Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
    Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
    J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
    Lepretre S; Jäger U; Janssens A; Leblond V; Nikitin E; Robak T; Wendtner CM
    Leuk Lymphoma; 2012 May; 53(5):820-9. PubMed ID: 21992675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.
    Jaglowski SM; Alinari L; Lapalombella R; Muthusamy N; Byrd JC
    Blood; 2010 Nov; 116(19):3705-14. PubMed ID: 20610811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
    Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
    J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.
    Castro JE; Sandoval-Sus JD; Bole J; Rassenti L; Kipps TJ
    Leukemia; 2008 Nov; 22(11):2048-53. PubMed ID: 18754025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic lymphocytic leukemia.
    Ferrajoli A; O'Brien SM
    Semin Oncol; 2004 Apr; 31(2 Suppl 4):60-5. PubMed ID: 15124136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
    Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
    Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
    Schulz H; Klein SK; Rehwald U; Reiser M; Hinke A; Knauf WU; Aulitzky WE; Hensel M; Herold M; Huhn D; Hallek M; Diehl V; Engert A;
    Blood; 2002 Nov; 100(9):3115-20. PubMed ID: 12384407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
    Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Keating MJ; Flinn I; Jain V; Binet JL; Hillmen P; Byrd J; Albitar M; Brettman L; Santabarbara P; Wacker B; Rai KR
    Blood; 2002 May; 99(10):3554-61. PubMed ID: 11986207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine in chronic lymphocytic leukaemia.
    Elter T; Hallek M; Engert A
    Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Byrd JC; Rai KR
    Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.